Jerini collaborates with Baxter for protein purification

Under the terms of the agreement, Jerini will use its peptides-to-drugs (P2D) technology platform to identify and develop a specific binding molecule for protein purification, which potentially offers key advantages over conventional antibody-assisted protein purification. Jerini will receive an upfront payment and full time equivalents funding along with potential milestone payments for the achievement of discovery, preclinical and clinical goals and royalties on eventual product sales.

Jens Schneider-Mergener, CEO at Jerini, said: “We are very pleased to announce our fourth collaboration agreement with Baxter. Jerini’s proprietary P2D technology platform offers a unique and highly effective approach in the development of novel peptidomimetics or small molecules with applications in protein purification as well as drug development.”